These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19026033)

  • 1. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.
    Bring P; Ensom MH
    Clin Pharmacokinet; 2008; 47(12):767-78. PubMed ID: 19026033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of oxcarbazepine.
    May TW; Korn-Merker E; Rambeck B
    Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic drug monitoring of oxcarbazepine].
    Bouquié R; Dailly E; Bentué-Ferrer D;
    Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxcarbazepine: an update of its efficacy in the management of epilepsy.
    Wellington K; Goa KL
    CNS Drugs; 2001; 15(2):137-63. PubMed ID: 11460891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy.
    Wegner I; Edelbroek P; de Haan GJ; Lindhout D; Sander JW
    Epilepsia; 2010 Dec; 51(12):2500-2. PubMed ID: 21204816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxcarbazepine, an antiepileptic agent.
    Kalis MM; Huff NA
    Clin Ther; 2001 May; 23(5):680-700; discussion 645. PubMed ID: 11394728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
    Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
    Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
    Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
    Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of Oxcarbazepine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
    Johnson-Davis KL; Thomas RL
    Methods Mol Biol; 2024; 2737():387-395. PubMed ID: 38036839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
    Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
    Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
    Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
    Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology and pharmacokinetics of oxcarbazepine.
    Lloyd P; Flesch G; Dieterle W
    Epilepsia; 1994; 35 Suppl 3():S10-3. PubMed ID: 8156973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
    Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
    Schmutz M; Brugger F; Gentsch C; McLean MJ; Olpe HR
    Epilepsia; 1994; 35 Suppl 5():S47-50. PubMed ID: 8039471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
    Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
    Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of 10-hydroxycarbazepine by plasmapheresis.
    Christensen J; Balslev T; Villadsen J; Heinsvig EM; Dam M; Poulsen JH
    Ther Drug Monit; 2001 Aug; 23(4):374-9. PubMed ID: 11477319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
    Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.
    de Jesus Antunes N; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre V; Takayanagui OM; Tozatto E; Lanchote VL
    Chirality; 2013 Dec; 25(12):897-903. PubMed ID: 24123382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.